logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Vertex Pharmaceuticals Announces Advancements of Its Product Suzetrigine for Acute and Neuropathic Pain

Vertex Pharmaceuticals in the NEWS Vertex Pharmaceuticals ( VRTX ) announced advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Vertex’s...

Read More

April 18, 2024

0

The U.S. FDA Approved Immunity Bio's ANKTIVA® for the Treatment of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Immunity Bio in the NEWS Immunity Bio ( IBRX ) - an immunotherapy company, announced that the U.S. FDA has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin ( BCG ) for the treatment of patients with BCG-unresponsive...

Read More

April 23, 2024

0

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

Regeneron Pharmaceuticals and Mammoth Biosciences in the NEWS Regeneron Pharmaceuticals ( REGN ) and Mammoth Biosciences, Inc.  announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. Regeneron develops adeno-associated...

Read More

April 25, 2024

0

U.S. FDA Approved Pfizer’s BEQVEZ™ - A One-Time Gene Therapy for Adults with Hemophilia B

 Pfizer Approval A one-time dose of the Pfizer product, BEQVEZ, has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds (range 0 to 19) after up to three years of follow-up, providing sustained bleed protection...

Read More

April 26, 2024

0

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

From Akero Therapeutics  Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero Therapeutics remarked, "I am delighted to welcome Scott Gangloff to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enrich...

Read More

April 30, 2024

0

TG Therapeutics Stock Price is Rising as Q1 Revenues from BRIUMVI U.S. Have Exceeded Expectations

TG Therapeutics Financial Results for Q1 2024 TG Therapeutics, Inc. ( TGTX ) announced its financial results for the first quarter of 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “We...

Read More

May 1, 2024

0

CytomX is Rallying Today! The Firm Will Report Q1 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024  

CytomX Therapeutics  CytomX Therapeutics, Inc. ( CTMX ) announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose escalation update on Wednesday, May 8, 2024, after the close of U.S. markets. Following the...

Read More

May 1, 2024

0

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Crispr Therapeutics in the NEWS CRISPR Therapeutics ( CRSP ) announced new preclinical data presented at the 27th Annual Meeting of the American Society of Cell and Gene Therapy ( ASGCT ) highlighting the Company’s approach to developing lipid nanoparticle...

Read More

May 8, 2024

0

Jennifer Schneider Elected to Vertex Pharmaceuticals Board of Directors. Why It's Good News

Vertex Pharmaceuticals News Today, May 15, 2024, Vertex Pharmaceuticals ( VRTX ) announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Why is this news Great News? Dr. Schneider has more...

Read More

May 15, 2024

0

Autonomix Medical Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer 

Autonomix Medical Announcement May 23, 2024, Autonomix Medical ( AMIX ) announced successful completion of an animal study evaluating the ability of targeted nerve ablation to impact tumor metastases and growth. Two groups in a preclinical study of mice received...

Read More

May 23, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 170
  • 171
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy